Catalyst Biosciences Announces Issuance of Asia Patents Covering Factor IX Hemophilia Program
September 11 2017 - 8:01AM
-- CB 2679d/ISU304 has patent coverage in all key
commercial territories --
Catalyst Biosciences, Inc. (Nasdaq:CBIO), today announced that it
has been issued patents covering its coagulation Factor IX
hemophilia product candidate from the State Intellectual Property
Office (SIPO) in the People's Republic of China, the Intellectual
Property Office of Singapore (IPOS), and the Taiwan
Intellectual Property Office (TIPO). The patents cover both
modified Factor IX polypeptides and uses thereof, and build on the
Company’s extensive intellectual property portfolio.
"With the addition of these key Asian territories our Factor IX
program now has broad patent coverage in major markets including
the United States, Europe, China and Japan,” said Nassim Usman,
Ph.D., Catalyst’s President and Chief Executive Officer.
The Company’s Factor IX clinical development program currently
includes an ongoing Phase 1/2 proof-of-concept clinical trial to
evaluate the subcutaneous bioavailability and clotting ability of
CB 2679d. Catalyst believes that subcutaneous prophylactic therapy
of CB 2979d has the potential to provide greater convenience while
eliminating spontaneous bleeding in individuals with hemophilia
B.
About Factor IX CB 2679d/ISU304 is a
next-generation coagulation Factor IX variant that is being
evaluated in a Phase 1/2 proof-of-concept clinical trial
in South Korea. Data from the first Cohort of patients (n=3)
demonstrated that intravenous CB2679d is approximately 22 times
more potent than intravenous BeneFIX®. Additional interim, top-line
results of this open-label study are expected by the end of 2017
and complete trial results are expected to be available in early
2018. Catalyst believes that CB 2679d may allow for subcutaneous
prophylactic treatment of individuals with hemophilia B.
About Catalyst Catalyst is a clinical-stage
biopharmaceutical company focused on developing novel medicines to
address hematology indications. Catalyst is focused on the field of
hemostasis, including the subcutaneous prophylaxis of hemophilia
and facilitating surgery in individuals with hemophilia. For more
information, please visit www.catalystbiosciences.com.
Forward-Looking StatementsThis press release
contains forward-looking statements that involve substantial risks
and uncertainties. All statements, other than statement of
historical facts, included in this press release regarding our
strategy, the potential uses and benefits of CB 2679d and
development plans for this product candidate are forward-looking
statements. Examples of such statements include, but are not
limited to, statements relating to risks related to the Company’s
ability to protect or enforce intellectual property rights related
to its product candidates, Catalyst’s clinical trial timelines,
including the anticipated completion of a Phase 1/2
proof-of-concept study for CB 2679d or the plans to disclose
interim top-line results from the Phase 1/2 study by the end of
2017 and complete trial results by early 2018, and the potential
uses and benefits of subcutaneously dosed CB 2679d. Actual results
or events could differ materially from the plans and expectations
and projections disclosed in these forward-looking statements.
Various important factors could cause actual results or events to
differ materially from the forward-looking statements that Catalyst
makes, including, but not limited to, the risk that trials and
enrollment may be delayed and may not have satisfactory outcomes,
that human trials will not replicate the results from preclinical
studies or that later cohorts may not replicate results from
earlier cohorts of the same trial, that subcutaneous dosing of CB
2679d may not replicate potency or longevity of intravenous dosing,
that potential adverse effects may arise from the testing or use of
Catalyst’s products, including the generation of antibodies, the
risk that costs required to develop or manufacture Catalyst’s
products will be higher than anticipated, competition, and other
factors described in the “Risk Factors” section of the Company’s
most recent Quarterly Report on Form 10-Q filed with the SEC
on August 3, 2017. Catalyst does not assume any obligation to
update any forward-looking statements, except as required by
law.
Contacts:Investors: Fletcher Payne, CFO,
Catalyst Biosciences 650.871.0761investors@catbio.com
Media:Denise Powell510.703.9491denise@redhousecomms.com
Catalyst Biosciences (NASDAQ:CBIO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Catalyst Biosciences (NASDAQ:CBIO)
Historical Stock Chart
From Apr 2023 to Apr 2024